Purpose: To assess the influence of age-related macular degeneration (AMD) on critical flicker-fusion frequency (CFF).
Methods: CFF was measured centrally for a red, green and blue target, and in 10 degrees excentricity with a red target. Twenty-eight patients with non-exsudative AMD, 12 patients with exsudative AMD and 45 age-matched healthy eyes were included.
Results: CFF decreased in eyes with non-exsudative AMD (red 1.3 Hz, p=0.025; green 1.4 Hz, p=0.053; blue 2.1 Hz, p=0.006) and exsudative AMD (red 2.2 Hz, p=0.02; green 3.3 Hz, p=0.001; blue 2.9 Hz, p=0.02). The difference between central and peripheral CFF increased in non-exsudative AMD (red-red 10 degrees, 0.7 Hz, p=0.024), but was not significantly increased in exsudative AMD (1.3 Hz, p=0.059). There was no difference between eyes with non-exsudative AMD with good visual acuity (VA >20/32, n=18) and healthy eyes, nor between eyes with non-exsudative (n=10) and exsudative AMD (n=9) with VA from 20/100 to 20/40.
Conclusions: CFF decreased in non-exsudative and exsudative AMD. CFF is not able to distinguish between AMD eyes and healthy eyes of equal visual acuity, and therefore is not applicable as a possible diagnostic test.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00417-009-1270-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Anti-VEGF therapy is the standard treatment for exudative neovascular age-related macular degeneration (nAMD) caused by the development of macular neovascularisation (MNV) with associated fluid exudation. The therapeutic strategies (T&E or PRN) assumed a scarring transformation of the MNV and exit strategies and were formulated accordingly. The present study investigates this hypothesis as a real-life long-term analysis.
View Article and Find Full Text PDFVisual Outcomes after Anti-VEGF Therapy for Exudative Age-Related Macular Degeneration in a Real-Life Setting.
Klin Monbl Augenheilkd
April 2021
Department of Ophthalmology, Cantonal Hospital St. Gallen, Switzerland.
Background: To report visual outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy for exudative age-related macular degeneration (AMD) in a real-life setting.
Patients And Methods: Retrospective case series of consecutive patients treated with either ranibizumab and/or aflibercept for monolateral or bilateral exudative AMD. A physician established the indication for treatment and administered the injections.
[Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years].
J Fr Ophtalmol
May 2021
Clinique ophtalmologique, CHU de Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France.
Introduction: The objective of this study was to analyze the reproducibility or variability of the time period to exudative recurrences in patients who were treated with intravitreal injections (IVT) of anti-VEGF (ranibizumab, aflibercept) for exudative age-related macular degeneration (AMD). The data studied included the number of recurrences per year, the time between the last IVT and the recurrence, fluctuation over time in the same patient, and changes in the therapeutic management of these exudative recurrences with regard to repeat induction therapy of three IVT, changes in monitoring protocols, and switches in anti-VEGF molecules.
Materials And Methods: We conducted a retrospective, single center, "real-life" study at the Nantes University Hospital, including 33 patients (42 eyes) between March 2012 and March 2017.
[Treat-and-extend anti-angiogenic protocol in clinical practice for patients with exudative age-related macular degeneration: Consensus of French experts].
J Fr Ophtalmol
January 2021
Département ophtalmologie, hôpital lariboisière, AP-HP, université Paris 7 - Sorbonne Paris Cité, Paris, France.
Optimizing treatment regimens for anti-angiogenic drugs is now a major issue in the management of patients with exudative AMD. The evolution of these approaches has led retinologists to favor so-called proactive administration regimens, such as Treat-and-Extend (T&E), which make it possible to anticipate recurrence and to plan intravitreal injections of anti-angiogenic drugs in advance. Nevertheless, a real need to standardize the application of this regimen has been identified.
View Article and Find Full Text PDF[Treatment of hematomas in age related macular degeneration by vitrectomy and subretinal injection of r-tPA: Preliminary results (French translation of the article)].
J Fr Ophtalmol
January 2020
Department of ophthalmology, CHRU Nancy-Brabois, rue du Morvan, 54500 Vandoeuvre-lès-Nancy.
Purpose: To evaluate anatomical and functional outcomes of surgical displacement of macular hemorrhages complicating exsudative age-related macular degeneration (AMD) after vitrectomy, subretinal rtPA (recombinant tissue plasminogen activator) injection, intravitreal bevacizumab injection and gaz tamponade.
Methods: Retrospective case series, including 26 patients with submacular hemorrhage, who underwent a surgical displacement within 15 days after the onset of symptoms. Optical coherence tomography (OCT) was carried out to measure the diameter of the hemorrhage and to specify the relation with retinal pigment epithelium.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!